Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs Wellorithm

GoodRx
Graded #122

Higher grade

vs+21.099999999999994
Wellorithm
Graded #486

Lower grade

The verdict

GoodRx takes it — 69.6/100 to 48.5/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +50
80
30
Dose & formulationWellorithm +22
70
92
Clinical oversightGoodRx +41
69
28
Labs & monitoringGoodRx +11
51
40
FulfillmentGoodRx +19
81
62
Contract termsGoodRx +10
55
45
GoodRx · left barWellorithm · right bar

The numbers

MetricGoodRxWellorithm
WeighScore69.6/10048.5/100
GradeCC
Scorecard rank#122#486
SemaglutideNot disclosedPricing not published
Tirzepatide$299/mo (brand Zepbound)Pricing not published
CoverageAll 50 states49 states (not Louisiana)
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
GoodRx

Graded #122 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
Wellorithm

Graded #486 · C

Strengths

  • Both molecules in BOTH routes — compounded semaglutide and tirzepatide as injections and as oral dissolving tablets
  • Four branded pens on the same account: Mounjaro, Ozempic, Wegovy and Zepbound
  • Sermorelin offered alongside the GLP-1 line
  • 24/7 phone support on a published number

Where it loses points

  • No price appears anywhere on the public site — /pricing 404s and every product CTA leads to a 2-minute intake quiz, so no cost can be compared before signing up
  • The site contradicts itself on coverage: the homepage says "Serving All 50 States" while its own FAQ says 49 states and excludes Louisiana
  • The four clinicians presented as "board-certified obesity specialists" are listed as Cardiac Surgery, Pediatric Clinic, Gynecology and Cardiac Surgery — none in obesity medicine
  • "100% Customer Satisfaction" is stated as a headline fact and is not a substantiable claim

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard